Jean-Luc Fellahi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jean-Luc Fellahi has a total of 156 co-authors. Here are the top co-authors by number of shared publications:
- Matthias Jacquet-Lagrèze
Service d’anesthésie-réanimation, Hôpital cardiologique Louis Pradel, Hospices Civils de Lyon, Bron, France
8 shared publications - Martin Ruste
Service d’anesthésie-reanimation, Hôpital Louis Pradel, Bron Cedex, France
6 shared publications - Marc-Olivier Fischer
Institut Aquitain du Cœur, Clinique Saint-Augustin, Elsan, Bordeaux, France
4 shared publications - Jean-Luc Hanouz
Service d’anesthésie et réanimation chirurgicale, Centre Hospitalier Universitaire de Caen Normandie, Caen, Normandy, France
3 shared publications Laure Cazenave
Service d'anesthésie-Réanimation, Hôpital Universitaire Louis Pradel, Hospices Civils de Lyon; 59, Boulevard Pinel, 69677, Bron Cedex, France
3 shared publicationsMatthias Jacquet-Lagrèze
Service d’Anesthésie-Réanimation, Hôpital Louis Pradel, Hospices Civils de Lyon
3 shared publications
Latest Publications
- Open Access
- 6 November 2026
- Published by Wolters Kluwer Health in Anesthesiology
Individualized mean arterial pressure during cardiac surgery The OPTIPAM Randomized Clinical Trial
Background: Whether targeting an individualized mean arterial pressure (MAP) during cardiac surgery improves outcomes remains uncertain. The balance between improved perfusion and vasopressor-driven blood pressure augmentation is unclear. Methods: In this single-blind, multicenter randomized clinical trial conducted in 10 tertiary centers in France, adult patients undergoing elective cardiac surgery with cardiopulmonary bypass were assigned to either individualized MAP management (target within ±10% of preoperative baseline during surgery and for 24 h postoperatively) or standard management (target MAP ≥65 mm Hg). The primary outcome was a composite of all-cause death, acute kidney injury, or prespecified neurologic complications within 7 days. Safety outcomes included hemorrhagic complications and transfusion requirements. Results: A total of 172 patients were enrolled before the trial was stopped early by the data and safety monitoring board because of increased bleeding in the individualized group. Mean intraoperative MAP was higher with individualized management (80.6 vs 75.6 mm Hg; P<0.001), despite limited target adherence (33% of intraoperative time) and greater vasopressor use. The primary outcome occurred in 27 of 85 patients (32%) in the individualized group and 25 of 87 (29%) in the standard group (relative risk, 1.1; 95% CI, 0.7 to 1.8; P=0.76). Hemorrhagic complications occurred more frequently in the individualized group (18% vs 3%; P=0.003). Conclusions: In patients undergoing cardiac surgery, it was not possible to determine whether an individualized MAP strategy reduced major postoperative complications. More bleeding complications were observed in the individualized group. Future studies should further investigate this safety signal when evaluating individualized blood pressure targets.
- 6 November 2026
- Published by Wolters Kluwer Health in Anesthesiology
Open AccessIndividualized mean arterial pressure during cardiac surgery The OPTIPAM Randomized Clinical Trial
Background: Whether targeting an individualized mean arterial pressure (MAP) during cardiac surgery improves outcomes remains uncertain. The balance between improved perfusion and vasopressor-driven blood pressure augmentation is unclear. Methods: In this single-blind, multicenter randomized clinical trial conducted in 10 tertiary centers in France, adult patients undergoing elective cardiac surgery with cardiopulmonary bypass were assigned to either individualized MAP management (target within ±10% of preoperative baseline during surgery and for 24 h postoperatively) or standard management (target MAP ≥65 mm Hg). The primary outcome was a composite of all-cause death, acute kidney injury, or prespecified neurologic complications within 7 days. Safety outcomes included hemorrhagic complications and transfusion requirements. Results: A total of 172 patients were enrolled before the trial was stopped early by the data and safety monitoring board because of increased bleeding in the individualized group. Mean intraoperative MAP was higher with individualized management (80.6 vs 75.6 mm Hg; P<0.001), despite limited target adherence (33% of intraoperative time) and greater vasopressor use. The primary outcome occurred in 27 of 85 patients (32%) in the individualized group and 25 of 87 (29%) in the standard group (relative risk, 1.1; 95% CI, 0.7 to 1.8; P=0.76). Hemorrhagic complications occurred more frequently in the individualized group (18% vs 3%; P=0.003). Conclusions: In patients undergoing cardiac surgery, it was not possible to determine whether an individualized MAP strategy reduced major postoperative complications. More bleeding complications were observed in the individualized group. Future studies should further investigate this safety signal when evaluating individualized blood pressure targets.
- 6 May 2026
- Published by Wolters Kluwer Health in European Journal of Anaesthesiology
- Vol. 43 (6) , 499-502
Pro: we should fully utilise the preload reserve in high-risk patients undergoing noncardiac surgery
In high-risk surgical patients undergoing noncardiac procedures, volume expansion through the titrated administration of small fluid challenges following anaesthesia induction does not lead to excessive cumulative fluid balance compared to standard care. This strategy may contribute to the prevention of haemodynamic instability and occult hypoperfusion, especially within critical vascular beds. In this context, the French guidelines recommend the prophylactic optimisation of stroke volume through titrated fluid administration as a physiologically justified and clinically appropriate practice that should be routinely adopted by anaesthesiologists in the operating room.
- 6 May 2026
- Published by Wolters Kluwer Health in European Journal of Anaesthesiology
- Vol. 43 (6) , 499-502
Pro: we should fully utilise the preload reserve in high-risk patients undergoing noncardiac surgery
In high-risk surgical patients undergoing noncardiac procedures, volume expansion through the titrated administration of small fluid challenges following anaesthesia induction does not lead to excessive cumulative fluid balance compared to standard care. This strategy may contribute to the prevention of haemodynamic instability and occult hypoperfusion, especially within critical vascular beds. In this context, the French guidelines recommend the prophylactic optimisation of stroke volume through titrated fluid administration as a physiologically justified and clinically appropriate practice that should be routinely adopted by anaesthesiologists in the operating room.
- Open Access
- 26 September 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (19) , 6835
Prevention and Treatment of New-Onset Postoperative Atrial Fibrillation in the Acute Care Setting: A Narrative Review
New-onset postoperative atrial fibrillation (POAF) is common after cardiac and major noncardiac surgery and significantly associated with short- and long-term adverse events. Multiple management strategies have been described but the lack of evidence from large randomized controlled trials and the lack of consensus regarding best practices has led to major variations in practice patterns. Considering on the one hand its serious adverse effects and complex drug interactions, and on the other hand discrepancies among recent international guidelines, the indications of amiodarone to both prevent and treat POAF should be reserved to patients at high risk of POAF only, or patients with hemodynamic instability and/or severely reduced left ventricular ejection fraction. Perioperative optimization of oral and intravenous cardio-selective beta-blockers to prevent POAF, and control heart rate when POAF occurs with a rapid ventricular response is the recommended first-line strategy, simultaneously with the treatment of associated factors. Given their efficient and safe profile, ultra-short-acting intravenous beta-blockers like esmolol or landiolol could be preferentially used in acute care patients. Besides waiting for the results of ongoing RCTs in cardiac and noncardiac surgery, the use of oral anticoagulation in patients with POAF should take into account the individualized thromboembolic/hemorrhagic risk ratio.
- 26 September 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (19) , 6835
Open AccessPrevention and Treatment of New-Onset Postoperative Atrial Fibrillation in the Acute Care Setting: A Narrative Review
New-onset postoperative atrial fibrillation (POAF) is common after cardiac and major noncardiac surgery and significantly associated with short- and long-term adverse events. Multiple management strategies have been described but the lack of evidence from large randomized controlled trials and the lack of consensus regarding best practices has led to major variations in practice patterns. Considering on the one hand its serious adverse effects and complex drug interactions, and on the other hand discrepancies among recent international guidelines, the indications of amiodarone to both prevent and treat POAF should be reserved to patients at high risk of POAF only, or patients with hemodynamic instability and/or severely reduced left ventricular ejection fraction. Perioperative optimization of oral and intravenous cardio-selective beta-blockers to prevent POAF, and control heart rate when POAF occurs with a rapid ventricular response is the recommended first-line strategy, simultaneously with the treatment of associated factors. Given their efficient and safe profile, ultra-short-acting intravenous beta-blockers like esmolol or landiolol could be preferentially used in acute care patients. Besides waiting for the results of ongoing RCTs in cardiac and noncardiac surgery, the use of oral anticoagulation in patients with POAF should take into account the individualized thromboembolic/hemorrhagic risk ratio.
- Open Access
- 4 August 2025
- Published by MDPI AG in Preprints.org
Prevention and Treatment of New-Onset Postoperative Atrial Fibrillation in the Acute Care Setting: A Narrative Review
New-onset postoperative atrial fibrillation (POAF) is common after cardiac and major noncardiac surgery, and significantly associated with short- and long-term adverse events. Multiple management strategies have been described but the lack of evidence from large randomized controlled trials and the lack of consensus regarding best practices has led to major variations in practice patterns. Considering on the one hand its serious adverse effects and complex drug interactions, and on the other hand discrepancies among recent international guidelines, the indications of amiodarone to both prevent and treat POAF should be reserved to patients at high risk of POAF only, or patients with hemodynamic instability and/or severely reduced left ventricular ejection fraction. Perioperative optimization of oral and intravenous cardio-selective beta-blockers to prevent POAF, and control heart rate when POAF occurs with a rapid ventricular response is the recommended first-line strategy, simultaneously with the treatment of associated factors. Given their efficient and safety profile, ultra-short-acting intravenous beta-blockers like esmolol or landiolol could be preferentially used in acute care patients. Besides, and waiting for the results of ongoing RCTs in cardiac and noncardiac surgery, the use of oral anticoagulation in patients with POAF should take into account the individualized thromboembolic/hemorrhagic risk ratio.
- 4 August 2025
- Published by MDPI AG in Preprints.org
Open AccessPrevention and Treatment of New-Onset Postoperative Atrial Fibrillation in the Acute Care Setting: A Narrative Review
New-onset postoperative atrial fibrillation (POAF) is common after cardiac and major noncardiac surgery, and significantly associated with short- and long-term adverse events. Multiple management strategies have been described but the lack of evidence from large randomized controlled trials and the lack of consensus regarding best practices has led to major variations in practice patterns. Considering on the one hand its serious adverse effects and complex drug interactions, and on the other hand discrepancies among recent international guidelines, the indications of amiodarone to both prevent and treat POAF should be reserved to patients at high risk of POAF only, or patients with hemodynamic instability and/or severely reduced left ventricular ejection fraction. Perioperative optimization of oral and intravenous cardio-selective beta-blockers to prevent POAF, and control heart rate when POAF occurs with a rapid ventricular response is the recommended first-line strategy, simultaneously with the treatment of associated factors. Given their efficient and safety profile, ultra-short-acting intravenous beta-blockers like esmolol or landiolol could be preferentially used in acute care patients. Besides, and waiting for the results of ongoing RCTs in cardiac and noncardiac surgery, the use of oral anticoagulation in patients with POAF should take into account the individualized thromboembolic/hemorrhagic risk ratio.
- 15 October 2024
- Published by Wolters Kluwer Health in Anesthesia & Analgesia
- Vol. 140 (1) , 228-230
High-Sensitivity Troponin I Release After Aortic Surgery: A Mechanistic Approach with Contrast-Enhanced Magnetic Resonance Imaging (the MITEC Study)
- 15 October 2024
- Published by Wolters Kluwer Health in Anesthesia & Analgesia
- Vol. 140 (1) , 228-230
High-Sensitivity Troponin I Release After Aortic Surgery: A Mechanistic Approach with Contrast-Enhanced Magnetic Resonance Imaging (the MITEC Study)
- Open Access
- 19 June 2024
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 11, 1424188
Myocardial protection in cardiac surgery: a comprehensive review of current therapies and future cardioprotective strategies
Cardiac surgery with cardiopulmonary bypass results in global myocardial ischemia–reperfusion injury, leading to significant postoperative morbidity and mortality. Although cardioplegia is the cornerstone of intraoperative cardioprotection, a number of additional strategies have been identified. The concept of preconditioning and postconditioning, despite its limited direct clinical application, provided an essential contribution to the understanding of myocardial injury and organ protection. Therefore, physicians can use different tools to limit perioperative myocardial injury. These include the choice of anesthetic agents, remote ischemic preconditioning, tight glycemic control, optimization of respiratory parameters during the aortic unclamping phase to limit reperfusion injury, appropriate choice of monitoring to optimize hemodynamic parameters and limit perioperative use of catecholamines, and early reintroduction of cardioprotective agents in the postoperative period. Appropriate management before, during, and after cardiopulmonary bypass will help to decrease myocardial damage. This review aimed to highlight the current advancements in cardioprotection and their potential applications during cardiac surgery.
- 19 June 2024
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 11, 1424188
Open AccessMyocardial protection in cardiac surgery: a comprehensive review of current therapies and future cardioprotective strategies
Cardiac surgery with cardiopulmonary bypass results in global myocardial ischemia–reperfusion injury, leading to significant postoperative morbidity and mortality. Although cardioplegia is the cornerstone of intraoperative cardioprotection, a number of additional strategies have been identified. The concept of preconditioning and postconditioning, despite its limited direct clinical application, provided an essential contribution to the understanding of myocardial injury and organ protection. Therefore, physicians can use different tools to limit perioperative myocardial injury. These include the choice of anesthetic agents, remote ischemic preconditioning, tight glycemic control, optimization of respiratory parameters during the aortic unclamping phase to limit reperfusion injury, appropriate choice of monitoring to optimize hemodynamic parameters and limit perioperative use of catecholamines, and early reintroduction of cardioprotective agents in the postoperative period. Appropriate management before, during, and after cardiopulmonary bypass will help to decrease myocardial damage. This review aimed to highlight the current advancements in cardioprotection and their potential applications during cardiac surgery.
- 29 May 2024
- Published by Springer Nature
- p. 323-337
The Surgical Critically Ill Patients: A Focus on Deresuscitation Strategy
- 29 May 2024
- Published by Springer Nature
- p. 323-337
The Surgical Critically Ill Patients: A Focus on Deresuscitation Strategy
- 7 April 2023
- Published by Wolters Kluwer Health in Current Opinion in Critical Care
- Vol. 29 (3) , 259-267
Advantages and limitations of noninvasive devices for cardiac output monitoring: a literature review
Purpose of review: Individualized hemodynamic optimization often requires cardiac output monitoring, mostly for goal-directed therapy in the operating room and fluid responsiveness assessment in the intensive care unit. Different technologies for noninvasive cardiac output determination have become available over the recent years. It is therefore crucial for care providers to be made aware of the advantages and limitations of those different devices for an appropriate use at the bedside. Recent findings: Nowadays, different noninvasive technologies exist, each with their advantages and limitations, but none are considered interchangeable with bolus thermodilution. Different clinical studies however, emphasize that the trending ability of such devices allows to guide decisions from care providers, and that their use may be associated with improved prognosis, especially in the operating room. Recent studies have also reported their potential use for hemodynamic optimization in specific populations. Summary: Noninvasive cardiac output monitoring may have a clinical impact on patient outcomes. Further studies are required to evaluate their clinical relevance, notably in the intensive care unit. Noninvasive monitoring opens up the possibility for hemodynamic optimization in specific or low-risk populations, the benefit of which remains to be assessed.
- 7 April 2023
- Published by Wolters Kluwer Health in Current Opinion in Critical Care
- Vol. 29 (3) , 259-267
Advantages and limitations of noninvasive devices for cardiac output monitoring: a literature review
Purpose of review: Individualized hemodynamic optimization often requires cardiac output monitoring, mostly for goal-directed therapy in the operating room and fluid responsiveness assessment in the intensive care unit. Different technologies for noninvasive cardiac output determination have become available over the recent years. It is therefore crucial for care providers to be made aware of the advantages and limitations of those different devices for an appropriate use at the bedside. Recent findings: Nowadays, different noninvasive technologies exist, each with their advantages and limitations, but none are considered interchangeable with bolus thermodilution. Different clinical studies however, emphasize that the trending ability of such devices allows to guide decisions from care providers, and that their use may be associated with improved prognosis, especially in the operating room. Recent studies have also reported their potential use for hemodynamic optimization in specific populations. Summary: Noninvasive cardiac output monitoring may have a clinical impact on patient outcomes. Further studies are required to evaluate their clinical relevance, notably in the intensive care unit. Noninvasive monitoring opens up the possibility for hemodynamic optimization in specific or low-risk populations, the benefit of which remains to be assessed.
- 1 December 2022
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 130 (2) , e193-e194
Fluids, vasopressors, and acute kidney injury after major abdominal surgery. Comment on Br J Anaesth 2022; 129: 317–26
- 1 December 2022
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 130 (2) , e193-e194
Fluids, vasopressors, and acute kidney injury after major abdominal surgery. Comment on Br J Anaesth 2022; 129: 317–26
- 19 September 2022
- Published by Oxford University Press (OUP) in Journal Of Nephrology
- Vol. 36 (1) , 187-197
Refilling and preload dependence failed to predict cardiac index decrease during fluid removal with continuous renal replacement therapy
Background: Fluid removal can reduce the burden of fluid overload after initial resuscitation. According to the Frank-Starling model, iatrogenic hypovolemia should induce a decrease in cardiac index. We hypothesized that inadequate refilling detected by haemoconcentration during fluid removal or an increase in cardiac index (CI) during passive leg raising (PLR) could predict CI decrease during mechanical fluid removal with continuous renal replacement therapy (CRRT). Methods: We conducted a single-centre prospective diagnostic accuracy study. The primary objective was to investigate the diagnostic performance of plasma protein concentration variations in detecting a CI decrease ≥ 12% during mechanical fluid removal. Secondary objective was to assess other predictive factors of CI change. The attending physician prescribed a fluid removal challenge consisting of a mechanical fluid removal challenge of 500 mL for one hour. Plasma protein concentration, haemoglobin level, PLR and transpulmonary thermodilution were done before and after the fluid removal challenge. Results: We included 69 adult patients between December 2016 and April 2020. Sixteen patients had a significant CI decrease (23% [95% CI 14–35]). Haemoconcentration and PLR before fluid removal challenge or CI trending failed to predict CI decrease. Conclusion: Haemoconcentration variables, preload dependence status and CI trending failed to predict CI decrease during fluid removal challenge.
- 19 September 2022
- Published by Oxford University Press (OUP) in Journal Of Nephrology
- Vol. 36 (1) , 187-197
Refilling and preload dependence failed to predict cardiac index decrease during fluid removal with continuous renal replacement therapy
Background: Fluid removal can reduce the burden of fluid overload after initial resuscitation. According to the Frank-Starling model, iatrogenic hypovolemia should induce a decrease in cardiac index. We hypothesized that inadequate refilling detected by haemoconcentration during fluid removal or an increase in cardiac index (CI) during passive leg raising (PLR) could predict CI decrease during mechanical fluid removal with continuous renal replacement therapy (CRRT). Methods: We conducted a single-centre prospective diagnostic accuracy study. The primary objective was to investigate the diagnostic performance of plasma protein concentration variations in detecting a CI decrease ≥ 12% during mechanical fluid removal. Secondary objective was to assess other predictive factors of CI change. The attending physician prescribed a fluid removal challenge consisting of a mechanical fluid removal challenge of 500 mL for one hour. Plasma protein concentration, haemoglobin level, PLR and transpulmonary thermodilution were done before and after the fluid removal challenge. Results: We included 69 adult patients between December 2016 and April 2020. Sixteen patients had a significant CI decrease (23% [95% CI 14–35]). Haemoconcentration and PLR before fluid removal challenge or CI trending failed to predict CI decrease. Conclusion: Haemoconcentration variables, preload dependence status and CI trending failed to predict CI decrease during fluid removal challenge.